Logo-apb
Adv Pharm Bull. 2024;14(3): 543-557.
doi: 10.34172/apb.2024.059
  Abstract View: 315
  PDF Download: 200

Review Article

Novel Advances in Cell-Free Therapy for Premature Ovarian Failure (POF): A Comprehensive Review

Yahya Yahyavi 1 ORCID logo, Niloufar Kheradi 2 ORCID logo, Abbas Karimi 1 ORCID logo, Abbas Ebrahimi-Kalan 3 ORCID logo, Fatemeh Ramezani 1 ORCID logo, Soudabe Yousefi 4 ORCID logo, Shirin Teymouri Nobari 5 ORCID logo, Hourieh Sadrekarimi 6 ORCID logo, Mohammad Nouri 4* ORCID logo, Mahdi Edalati 7* ORCID logo

1 Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Neurosciences and Cognition, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
5 Department of Clinical Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
6 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran.
7 Department of Laboratory Science, Faculty of Paramedicine, Tabriz University of Medical Sciences, Tabriz, Iran.
*Corresponding Authors: Mohammad Nouri, Email: prof.m.nouri1960@gmail.com; Mahdi Edalati, Email: medalati61@gmail.com

Abstract

Premature ovarian failure (POF), is a condition characterized by the early decline of ovulation function. POF is a complex disorder that can be caused by various factors, and the idiopathic form represents a significant proportion of POF patients. Hormone replacement therapy (HRT) is currently considered the first-line treatment for POF. This review aims to provide a comprehensive overview of recent advancements in platelet-rich plasma (PRP), in vitro activation (IVA), stem cell therapy, exosome therapy, microRNAs, and mitochondrial targeting therapies as a promising cell-free therapeutic approach in reproductive medicine. PLT-Exos, a new generation of cells, has been used to treat POF for more than a decade and has been shown to attenuate oocyte morphology and promote the differentiation of theca cells through the upregulation of PI3K/Akt and Bcl2, as well as the downregulation of the Smad and Bax signaling pathways. This review summarizes the current state of the art in the field of PLT-Exos and discusses the advantages and limitations of their potential clinical applications.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 316

Your browser does not support the canvas element.


PDF Download: 200

Your browser does not support the canvas element.

Submitted: 19 Feb 2024
Revision: 23 Jun 2024
Accepted: 30 Jul 2024
ePublished: 31 Jul 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)